Premium
Danazol in treatment of angio‐immunoblastic lymphadenopathy
Author(s) -
Banavali Shripad D.,
Parikh Purvish M.,
Charak Bishan Singh,
Modi Alok,
Iyer Rajaraman,
Nadkarni Kanchan S.,
Saikia Tapan,
Gopal Ramakrishnan,
Soman Chitralekna S.,
Advani Suresh H.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890801)64:3<613::aid-cncr2820640308>3.0.co;2-k
Subject(s) - danazol , medicine , disease , chemotherapy , regimen , immunology , pathology , dermatology , surgery , endometriosis
The clinical manifestations of angio‐immunoblastic lymphadenopathy (AILD) suggest that there is an abnormality in the immune system. Most patients with AILD die from opportunistic infections associated with lymphocyte depletion. As chemotherapy further increases the already high susceptibility of infections, the therapeutic management of AILD is difficult. The achievement of complete remission (CR) by the patient described here using a danazol‐based regimen raises the hope that treatment of this disease with a noncytotoxic drug may be possible. The rationale behind and advantages of using danazol are discussed.